BFM
ALBO

Boothbay Fund Management’s Albireo Pharma Inc ALBO Stock Holding History

Boothbay Fund Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-114
Closed -$302K – 1305
2020
Q2 		$302K Buy
+114
New +$2.69K 0.02% 695

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Boothbay Fund Management's ALBO Position: Q4 2021 in Review

Boothbay Fund Management sold out of Albireo Pharma Inc (ALBO) in Q4 2021, closing a stake of 6,845 shares — an estimated $214K sold.

Boothbay Fund Management first reported a position in ALBO in Q4 2020 and held it in 3 quarters. The position peaked at $315K in Q4 2020. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2021.

  • Boothbay Fund Management reported no remaining Albireo Pharma Inc position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 6,845 Albireo Pharma Inc shares in Q4 2021, an estimated $214K.
  • Boothbay Fund Management first reported a position in Albireo Pharma Inc in Q4 2020 and held it in 3 quarters.
  • Boothbay Fund Management's Albireo Pharma Inc position peaked at $315K in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.